Funding for this research was provided by:
Text and Data Mining valid from 2018-10-08
Received: 19 April 2018
Revised: 6 September 2018
Accepted: 12 September 2018
First Online: 8 October 2018
Compliance with ethical standards
: All participants provided written informed consent to participate in the study, and the protocol was approved by the institutional review board for each study site.
: Funding for this study was provided by ViiV Healthcare. During the conduct of the study, K.R. received consultancy fees and/or research funding from GlaxoSmithKline and ViiV Healthcare. P.M. is an employee of Cogstate Ltd. D.A.W. participated in advisory boards convened by Gilead Sciences and Janssen Therapeutics. Merck and Co., Gilead Sciences, and GlaxoSmithKline have provided the University of North Carolina with funding for his research. C.B.S. received consultancy fees and/or research funding from GlaxoSmithKline, ViiV Healthcare, Merck, Schering-Plough, and Abbott. H.E. is an employee of the Alameda Health System/Highland Hospital. L.L.R. and M.S.S. are employees of ViiV Healthcare.
: L.L.R and M.S.S. are both employees of ViiV Healthcare; P.M. is an employee of Cogstate. K.R. and H.E. have no conflicts of interest. C.B.S. has received consultancy fees and/or research funding from GlaxoSmithKline and ViiV Healthcare. GlaxoSmithKline has provided the University of North Carolina at Chapel Hill with funding for D.A.W.’s research.